SPHD vs XBI
Invesco S&P 500 High Dividend Low Volatility ETF vs SPDR S&P Biotech ETF
- • SPHD has the lower expense ratio at 0.30% vs 0.35% for XBI.
- • SPHD pays a higher dividend yield (4.37%).
Side-by-side metrics
| Metric | SPHD | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.30% | 0.35% |
Dividend yield Trailing 12-month yield. | 4.37% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $3.31B | $8.30B |
YTD return | 5.90% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.55 | 1.09 |
P/E ratio | 16.75 | — |
Last price | $49.81 | $133.66 |
Inception | — | — |
Issuer | Invesco | State Street |
SPHD top holdings
| MO | Altria Group Inc | 3.46% |
| VZ | Verizon Communications Inc | 3.37% |
| PFE | Pfizer Inc | 2.93% |
| OKE | ONEOK Inc | 2.81% |
| KHC | The Kraft Heinz Co | 2.75% |
| VICI | VICI Properties Inc Ordinary Shares | 2.66% |
| DOC | Healthpeak Properties Inc | 2.63% |
| BEN | Franklin Resources Inc | 2.62% |
| O | Realty Income Corp | 2.45% |
| CAG | Conagra Brands Inc | 2.42% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About SPHD
SPHD (Invesco S&P 500 High Dividend Low Volatility ETF) is High-yield, low-volatility S&P 500 stocks. Managed by Invesco, the fund carries $3.3B in assets under management, an expense ratio of 0.30%, a dividend yield of 4.37%. Its largest holding is Altria Group Inc (MO), which represents 3.5% of the portfolio. Real Estate is the fund's largest sector exposure at 20.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.